(Q47173429)

English

Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus

scientific article published on 29 July 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

1 reference

based on heuristic

inferred from title

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Wenying Yang

1

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

Xiaoping Xing

2

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

Xiaofeng Lv

3

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

Yiming Li

4

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

Jianhua Ma

5

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

Guoyue Yuan

6

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

Feifei Sun

7

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

Wei Wang

8

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

Michael Woloschak

9

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

Valentina Lukashevich

10

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

Plamen Kozlovski

11

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

Wolfgang Kothny

12

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

all investigators

13

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

publication date

29 July 2014

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

Journal of diabetes

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

7

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

2

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

174-181

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

Prevalence of diabetes among men and women in China

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Pioglitazone and sulfonylureas: effectively treating type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Clinical pharmacokinetics and pharmacodynamics of vildagliptin

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Hypoglycemia in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Hypoglycemic symptoms in patients with type 2 diabetes in Asia-Pacific-Real-life effectiveness and care patterns of diabetes management: the RECAP-DM study

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Sulfonylurea Compounds Uncouple the Glucose Dependence of the Insulinotropic Effect of Glucagon-Like Peptide 1

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12169

21 January 2018

Identifiers

10.1111/1753-0407.12169

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24823599

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47173429&oldid=2143521837"